Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) executive chairman Geremy Thomas believes the company’s strategy of becoming the leading aggregator of innovative technology and innovative tests, including blood and wellness, will ensure its future as a “very lucrative and long-term business”.
As part of its focus on its UK clinics, he said the company had delisted in Canada and relisted on the AQSE while redomiciling to Guernsey.
Thomas noted that the company achieved revenue of £7.4mln for the six months to June 30, 2022, a 52% increase from the same period in 2021.
However, second-quarter revenue eased back from the first quarter due to a decline in coronavirus (COVID-19) testing.
“We are going through a transition from the COVID travel testing business which was tremendous for us,” Thomas told Proactive.
“We are in a good space; we have got sufficient cash to deliver our strategy.”